Medinotec Inc. (MDNC) — SEC Filings

Medinotec Inc. (MDNC) — 12 SEC filings. Latest: 10-Q (Oct 8, 2025). Includes 6 10-Q, 4 8-K, 2 10-K.

View Medinotec Inc. on SEC EDGAR

Overview

Medinotec Inc. (MDNC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Oct 8, 2025: Medinotec Inc. reported significant revenue growth for the six months ended August 31, 2025, reaching $5,370,331, a substantial increase from $3,055,897 in the prior year period. Net income also rose to $460,350 for the six-month period, up from $371,953 in the same period last year. The company's g

Sentiment Summary

Across 12 filings, the sentiment breakdown is: 1 bearish, 9 neutral, 2 mixed. The dominant filing sentiment for Medinotec Inc. is neutral.

Filing Type Overview

Medinotec Inc. (MDNC) has filed 6 10-Q, 2 10-K, 4 8-K with the SEC between Feb 2024 to Oct 2025.

Filings by Year

2025 · 2024

Recent SEC Filings (12)

Medinotec Inc. SEC Filing History
DateFormDescriptionRisk
Oct 8, 202510-QMedinotec's Revenue Soars 76% Amidst Rising Operating Costsmedium
Jul 16, 202510-QMedinotec's Revenue Soars 600% on Minion Medical Boostmedium
May 29, 202510-KMedinotec's Revenue Soars 900% on Single Customer Reliancehigh
Jan 27, 20258-KMedinotec Inc. Files 8-K for Regulation FD and Financialslow
Jan 14, 202510-QMedinotec Inc. Files Q3 2024 10-Qlow
Oct 15, 202410-QMedinotec Inc. Files Q2 2024 10-Q Reportlow
Jul 12, 202410-QMedinotec Inc. Files Q1 2024 10-Q Reportlow
Jul 10, 20248-KMedinotec Inc. Changes Certifying Accountantlow
Jul 5, 202410-KMedinotec Inc. Files 2024 10-Klow
Mar 19, 20248-KMedinotec Inc. Files 8-K on Security Holder Votelow
Mar 14, 202410-QMedinotec Inc. Files 10-Q for Period Ending November 30, 2023low
Feb 26, 20248-KMedinotec Files 8-K: Regulation FD Disclosure & Financial Exhibitslow

Risk Profile

Risk Assessment: Of MDNC's 12 recent filings, 1 were flagged as high-risk, 2 as medium-risk, and 9 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Medinotec Inc. Financial Summary (10-Q, Oct 8, 2025)
MetricValue
Revenue$5.37M
Net Income$460,350
EPS$0.04
Debt-to-Equity0.30
Cash Position$2.25M
Operating Margin26.7%
Total Assets$6.37M
Total Debt$0.44M

Industry Context

Medinotec operates within the medical device manufacturing sector, which is characterized by rigorous regulatory oversight, significant R&D investment, and a competitive landscape. The company's focus on specialized respiratory devices, like the Trachealator, positions it within a niche segment. Success hinges on technological innovation, FDA approvals, and effective market penetration strategies, particularly in expanding into new geographic markets like the U.S.

Top Tags

10-Q (4) · Revenue Growth (3) · quarterly-report (3) · Medical Devices (2) · South Africa (2) · Customer Concentration (2) · Medical Instruments (2) · SEC Filing (2) · regulation-fd (2) · financial-statements (2)

Key Numbers

Medinotec Inc. Key Metrics
MetricValueContext
Revenue$5.37MIncreased from $3.06M for the six months ended August 31, 2024
Net Income$460,350Increased from $371,953 for the six months ended August 31, 2024
Gross Profit$2.93MIncreased from $1.43M for the six months ended August 31, 2024
Sales and Marketing Expenses$696,177Increased from $43,451 for the six months ended August 31, 2024
General and Administrative Expenses$1.30MIncreased from $631,014 for the six months ended August 31, 2024
Cash and Cash Equivalents$2.25MDecreased from $2.77M as of February 28, 2025
Repayment of Debt$980,467Cash outflow from financing activities for the six months ended August 31, 2025
Common Shares Outstanding11,755,548As of October 8, 2025
Basic Earnings Per Share$0.04For the six months ended August 31, 2025, up from $0.03
Revenue Growth75.7%Percentage increase for the six months ended August 31, 2025, compared to the prior year
Total Revenue$1.05MIncreased 600% from $150,000 in the prior year period.
Revenue from One Customer$900KRepresents 85.7% of total revenue, indicating high customer concentration.
Outside USA Internally Designed/Manufactured Sales$150KContribution to total revenue for the current quarter.
Outside USA Internally Designed Manufactured Sales$500,000Significant component of 2025 revenue, showing international sales focus.
Inside USA Internally Designed Manufactured Sales$300,000Contribution to 2025 revenue, indicating domestic market presence.

Frequently Asked Questions

What are the latest SEC filings for Medinotec Inc. (MDNC)?

Medinotec Inc. has 12 recent SEC filings from Feb 2024 to Oct 2025, including 6 10-Q, 4 8-K, 2 10-K. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of MDNC filings?

Across 12 filings, the sentiment breakdown is: 1 bearish, 9 neutral, 2 mixed. The dominant sentiment is neutral.

Where can I find Medinotec Inc. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Medinotec Inc. (MDNC) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Medinotec Inc.?

Key financial highlights from Medinotec Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for MDNC?

The investment thesis for MDNC includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Medinotec Inc.?

Executive information for Medinotec Inc. is extracted from SEC filings as they are enriched with AI analysis.

What are the main risk factors for Medinotec Inc. stock?

Of MDNC's 12 assessed filings, 1 were flagged high-risk, 2 medium-risk, and 9 low-risk.

What are recent predictions and forward guidance from Medinotec Inc.?

Forward guidance and predictions for Medinotec Inc. are extracted from SEC filings as they are enriched.

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.